Aimovig (Erenumab) – New Drug for Migraine Prevention
First FDA drug approved and designed to prevent migraines by targeting and blocking the calcitonin gene-related peptide (CGRP) receptor, disrupting a key component in the migraine pathophysiology.
Indicated for Episodic or Chronic migraines.
Based on the studies, patients with chronic and episodic migraines experienced 50% reduction in monthly migraine days over a period of 3 months and 4-6 months respectively.
Once monthly subcutaneous injection, designed to be self-administered.
Considering that this is a new drug, our providers at MCHN are administering the first dose and will teach you how to self-administer moving forward. They are also available to administer the injections monthly if that is your preference.
If you have chronic or episodic migraines, AIMOVIG could be the drug for you.
To learn more about aimovig, please call to schedule an appointment to discuss with one of our care providers.